What was Daiichi Sankyo's performance in the 21st period?

The performance in the 21st period saw a 10% increase in sales and a significant improvement in profits.

What are the key points to note in this report?

The key points to note are the expansion of new product sales and growth in overseas markets.

What is Daiichi Sankyo's future strategy?

The future strategy involves expanding R&D investment and strengthening global expansion.

What major technologies are mentioned in this report?

The report mentions the development of advanced pharmaceuticals and the introduction of digital healthcare technologies.

What are Daiichi Sankyo's main products?

Daiichi Sankyo's main products include anticancer drugs and diabetes treatments.

Daiichi Sankyo Co., Ltd. Securities Report - 21st Period (2025/04/01 - 2026/03/31)

Published Jun 19, 2026 9:57 PM ・ Updated Jun 20, 2026 7:44 AM ・ 2 min read ・ Source: PR Times

Daiichi Sankyo Co., Ltd. has published its 21st period securities report. The report details the company's performance and financial situation from April 1, 2025, to March 31, 2026. Sales increased by 10% compared to the previous year, and profits also improved significantly.

Daiichi Sankyo Co., Ltd. has published its 21st period securities report. This report details the company's performance and financial situation from April 1, 2025, to March 31, 2026.

Sales increased by 10% compared to the previous year, and profits also improved significantly. Notably, the expansion of new product sales and growth in overseas markets were highlighted, with a focus on expanding R&D investment and global expansion as future strategies.

Daiichi Sankyo Co., Ltd. is a leading Japanese pharmaceutical company established in 1928. Since its founding, the company has been dedicated to developing advanced pharmaceuticals and innovating medical technologies to provide high-quality medical care to patients worldwide. Particularly in the fields of anticancer drugs and diabetes treatments, Daiichi Sankyo has demonstrated global leadership.

As a future strategy, the company plans to expand R&D investment and strengthen global expansion. This aims to further enhance market competitiveness and achieve sustainable growth.

FACT BOX

Source: PR Times
Category: Funding

Daiichi Sankyo Co., Ltd. Securities Report - 21st Period (2025/04/01 - 2026/03/31)

⚡ Key Points

FACT BOX

Editorial & Verification Standards

FAQ

Cite this article — HOW TO CITE

AI CRAWLER ACTIVITY